Back to discover
Drug

Glutathione

In clinical development
Emerging researchLate-stage developmentCooling momentum
Also known as 5-L-Glutamyl-L-cysteinylglycine, GLYCINE, L-.GAMMA.-GLUTAMYL-L-CYSTEINYL-, GSH, L-Glutathione+6 more

5-L-Glutamyl-L-cysteinylglycine, GLYCINE, L-.GAMMA.-GLUTAMYL-L-CYSTEINYL-, GSH, L-Glutathione, N-(N-gamma-L-Glutamyl-L-cysteinyl)glycine, Navstel, gamma-L-Glutamyl-L-cysteinyl-glycine, Glutathion, Glutathione-L, Glutathione-SH.

9
Research papers
7
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study

Clinical trial2026-06-17Results expected Q2 2028 · ClinicalTrials.gov

Adia Med of Winter Park LLC Chronic Kidney Disease Research Study

Clinical trial2026-06-17Results expected Q1 2028 · ClinicalTrials.gov

Greater Atlanta Integrative Pediatrics Autism Spectrum Disorder Research Study

Clinical trial2026-06-03Results expected Q4 2026 · ClinicalTrials.gov

A Pilot Randomized Controlled Study of Combinatorial Gerotherapeutics for Healthspan Improvement

Clinical trial2026-04-01Primary completion · ClinicalTrials.gov

Redox regulation of the immune response.

Research2022-09-02Cellular & molecular immunology

Ferroptosis Mechanisms Involved in Neurodegenerative Diseases.

Research2020-11-20International journal of molecular sciences

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Glutathione
Aliases & brands
5-L-Glutamyl-L-cysteinylglycineGLYCINE, L-.GAMMA.-GLUTAMYL-L-CYSTEINYL-GSHL-GlutathioneN-(N-gamma-L-Glutamyl-L-cysteinyl)glycineNavstelgamma-L-Glutamyl-L-cysteinyl-glycineGlutathionGlutathione-LGlutathione-SH
RxNorm CUI
4890
ChEMBL ID
CHEMBL1543
ATC codes
V03AB32
UNII
GAN16C9B8O

Clinical trials

20 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
20
registered trials across all phases
LATEST COMPLETION 2020
7
Active studies
6
Recruiting
9
Late-stage (III+)
10
Completed
3
Discontinued
PHASE DISTRIBUTIONn = 20
Phase 15Phase 1 / 22Phase 24Phase 2 / 31Phase 33Phase 41Phase N / A4

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

9 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20132024
Most influential

The role of oxidative stress in Parkinson's disease.

Journal of Parkinson's disease · 2013 · 1,292 cites

Role of glutathione in cancer progression and chemoresistance.

Oxidative medicine and cellular longevity · 2013 · 765 cites

Redox regulation of the immune response.

Cellular & molecular immunology · 2022 · 319 cites
Major research themes8
Antioxidants2Glutathione2Disease Progression1Drug Resistance, Neoplasm1Ferroptosis1Neurodegenerative Diseases1NF-kappa B1Oxidative Stress1
Journals, researchers & institutions
Top journals
  • International journal of molecular sciences2
  • Biomolecules1
  • Cellular & molecular immunology1
  • Journal of Parkinson's disease1
  • Molecules (Basel, Switzerland)1
  • Nutrients1
Leading researchers
  • Ali A1
  • Azam M1
  • Banerji R1
  • Barros PL1
  • Bydlowski SP1
  • Choi I1
  • Cui YL1
  • Cuperlovic-Culf M1
Leading institutions
free-text, unnormalised
  • ACS Medical College and Hospital1
  • Brazilian Institute of Regenerative Medicine (BIRM)1
  • Center for Neurodegenerative and Neuroimmunologic Diseases1
  • Clinical Research1
  • Deakin University1
  • Digital Technologies Research Centre1

Related diseases

2 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Related drugs

6 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 3 of the same disease areas as Glutathione in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as Glutathione in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as Glutathione in the shared literature.

3 shared diseases1 shared paper

Studied across the same disease area as Glutathione in the shared literature.

1 shared disease1 shared paper

Studied across the same disease area as Glutathione in the shared literature.

1 shared disease1 shared paper

Frequently co-studied with Glutathione in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials